NCT01555047

Brief Summary

Genital ureaplasmas (Ureaplasma urealyticum and Ureaplasma parvum) and genital mycoplasmas (Mycoplasma hominis and Mycoplasma genitalium) are natural inhabitants of the male urethra contaminating the semen during ejaculation. However, these microorganisms, especially Ureaplasma urealyticum (Uu) and Mycoplasma hominis (Mh), are potentially pathogenic species playing an etiologic role in both genital infections and male infertility. Despite there are many consentaneous opinions about its relationship with infertility, its correlation with sperm regular parameters is still controversially. Sperm DNA damage can negatively influence fertilization rate, embryo cleavage rate, implantation rate, pregnancy and live birth rate, and is a novel indicator for intrauterine insemination (IUI) pregnancy rate and IVF or ICSI pregnancy loss rate. Until now, there were fewer clinical researches about the relationship among Uu and/or Mh infection, sperm DNA damage, and the IUI pregnancy rate. Thus, the investigators conduct this prospective study to investigate the relationship among them.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2011

Typical duration for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 15, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

April 10, 2013

Status Verified

April 1, 2013

Enrollment Period

2.3 years

First QC Date

March 9, 2012

Last Update Submit

April 8, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • pregnancy rate

    up to 3 monthes after IUI

Secondary Outcomes (1)

  • sperm DNA fragmentation index (DFI)

    one month before IUI

Study Arms (3)

males who were not infected by mycoplasma

ACTIVE COMPARATOR

100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.

Procedure: IUI

infected by mycoplasma males

EXPERIMENTAL

100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.

Procedure: IUI

fertile males

NO INTERVENTION

50 fertile males were chose as control samples

Interventions

IUIPROCEDURE

intrauterine insemination

males who were not infected by mycoplasma

Eligibility Criteria

Age20 Years - 50 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male with primary sterility with or without mycoplasma infection

You may not qualify if:

  • Combination with chlamydial infection
  • History of using hormone or cytotoxic drugs.
  • Having some other surgical diseases, such as genital tract infection or varicocele
  • Having some congenital diseases, such as Klinefelter and Y chromosome deficiency
  • Having some endocrine diseases, such as Kallmann, abnormality in pituitary gland, hyperthyroidism, hypercorticoidism, and so on
  • Patients' spouse had some diseases that could not carry out spontaneous pregnancy, such as tubal obstruction or ovulatory failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Mycoplasma Infections

Condition Hierarchy (Ancestors)

Mycoplasmatales InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical Attending Doctor

Study Record Dates

First Submitted

March 9, 2012

First Posted

March 15, 2012

Study Start

September 1, 2011

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

April 10, 2013

Record last verified: 2013-04